氨苄西林
无乳链球菌
微生物学
生物
抗生素耐药性
抗生素
大肠杆菌
青霉素
金黄色葡萄球菌
抗药性
细菌
链球菌
生物化学
基因
遗传学
作者
Xuanwei Chen,Jiahan Wu,Yingli Liu,Hetron Mweemba Munang’andu,Bo Peng
出处
期刊:Virulence
[Taylor & Francis]
日期:2023-02-20
卷期号:14 (1)
被引量:20
标识
DOI:10.1080/21505594.2023.2180938
摘要
Streptococcus agalactiae (GBS) is an important pathogenic bacteria that infected both aquatic animals and human beings, causing huge economic loss. The increasing cases of antibiotic-resistant GBS impose challenges to treat such infection by antibiotics. Thus, it is highly demanded for the approach to tackle antibiotic resistance in GBS. In this study, we adopt a metabolomic approach to identify the metabolic signature of ampicillin-resistant GBS (AR-GBS) that ampicillin is the routine choice to treat infection by GBS. We find glycolysis is significantly repressed in AR-GBS, and fructose is the crucial biomarker. Exogenous fructose not only reverses ampicillin resistance in AR-GBS but also in clinic isolates including methicillin-resistant Staphylococcus aureus (MRSA) and NDM-1 expressing Escherichia coli. The synergistic effect is confirmed in a zebrafish infection model. Furthermore, we demonstrate that the potentiation by fructose is dependent on glycolysis that enhances ampicillin uptake and the expression of penicillin-binding proteins, the ampicillin target. Our study demonstrates a novel approach to combat antibiotic resistance in GBS.
科研通智能强力驱动
Strongly Powered by AbleSci AI